Company intelligence / Profile preview

Nintamed

Germany

Ownership: Private
Development stage: Other

Overview

Nintamed served as Dexcom's exclusive distributor for CGM technologies in Germany, Switzerland, and Austria for six years prior to Dexcom's acquisition; clinical results are those of Dexcom's CGM products rather than Nintamed itself

Therapeutic areas: Endocrinology
Modalities: Device (specifically Continuous Glucose Monitoring (CGM) systems)
Industry: Physiological Monitoring

Partnerships

Dexcom (prior exclusive partnership, now fully owned)

Beyond the preview

Go deeper on Nintamed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nintamed.

Explore the full profile